Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial

What Was Tested

The paper reports a study of Liraglutide in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.

URL: https://www.clinicaltrials.gov; Unique identifier: NCT03948347.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This post hoc analysis of the LAMP trial (Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus; a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes.

Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone.

How the Study Was Run

The design is described as randomized, open-label and multicenter.

The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

Being open-label, the Liraglutide study did not mask who received what.

Running at several centres spread the Liraglutide study over different clinics and patient groups.

IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations.

Treatment-by-IR interactions were evaluated using Cox models.

What Was Measured

Topics PubMed links to this paper include Liraglutide, Insulin Resistance, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Ischemic Stroke, Stroke and Recurrence.

Author keywords: glucagon-like peptide-1 receptor agonists and ischemic attack, transient.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Liraglutide in people with insulin resistance, prediabetes & type 2 diabetes.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Stroke), a journal based in United States.

More context: the Liraglutide compound page, Insulin resistance, prediabetes & type 2 diabetes research.